From: RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential
Cancer type | ALKBH5 expression | Target RNAs | Target pathways | Therapy | Ref |
---|---|---|---|---|---|
Glioblastoma | High | CHK1, RAD51 | Homologous recombination (HR) pathway | Radiotherapy | [83] |
Glioblastoma | High | SOX2 | Wnt5a/β-catenin signaling | Temozolomide | [85] |
Oral squamous cell carcinoma | High | FOXM1, NANOG | – | Cisplatin | [112] |
Bladder cancer | Low | CSNK2A1 | Glycolysis pathway | Cisplatin | [114] |
Pancreatic cancer | Low | WIF1 | Wnt signaling pathway | Gemcitabine | [121] |
BRCA-mutated epithelial ovarian cancers | Low | FZD10 | Wnt/β-catenin pathway | PARP inhibitor | [159] |
Intrahepatic Cholangiocarcinoma | High | PDL1 | – | Anti–PD-1 therapy | [132] |
Melanoma | High | MCT4 | – | Anti–PD-1 therapy | [133] |